Get started
AC Immune SAAC Immune SAAC Immune SA

AC Immune SA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ACIU chart


Full chart

ACIU upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪168.20 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.57 USD
Net income (FY)
‪−57.82 M‬ USD
Revenue (FY)
‪31.01 M‬ USD
Shares float
‪61.45 M‬
Beta (1Y)
1.28

Employees


Employees (FY)
172
Change (1Y)
+11 +6.83%
Revenue / Employee (1Y)
‪180.29 K‬ USD
Net income / Employee (1Y)
‪−336.14 K‬ USD

About AC Immune SA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Andrea Pfeifer
Website
acimmune.com
Headquarters
Lausanne
Founded
2003
ISIN
CH0329023102
FIGI
BBG00D0RHJ38
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ACIU news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ACIU.

Frequently Asked Questions


The current price of ACIU is 1.70 USD — it has increased by 0.29% in the past 24 hours. Watch AC Immune SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AC Immune SA stocks are traded under the ticker ACIU.
ACIU stock has risen by 15.20% compared to the previous week, the month change is a −14.75% fall, over the last year AC Immune SA has showed a −29.17% decrease.
We've gathered analysts' opinions on AC Immune SA future price: according to them, ACIU price has a max estimate of 17.18 USD and a min estimate of 8.62 USD. Watch ACIU chart and read a more detailed AC Immune SA stock forecast: see what analysts think of AC Immune SA and suggest that you do with its stocks.
ACIU reached its all-time high on Sep 28, 2016 with the price of 19.97 USD, and its all-time low was 1.43 USD and was reached on Apr 9, 2025. View more price dynamics on ACIU chart.
See other stocks reaching their highest and lowest prices.
ACIU stock is 6.63% volatile and has beta coefficient of 1.28. Track AC Immune SA stock price on the chart and check out the list of the most volatile stocks — is AC Immune SA there?
Today AC Immune SA has the market capitalization of ‪168.20 M‬, it has increased by 13.33% over the last week.
Yes, you can track AC Immune SA financials in yearly and quarterly reports right on TradingView.
AC Immune SA is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
ACIU earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.20 USD resulting in a 11.62% surprise. The estimated earnings for the next quarter are −0.23 USD per share. See more details about AC Immune SA earnings.
AC Immune SA revenue for the last quarter amounts to ‪1.26 M‬ USD, despite the estimated figure of ‪819.45 K‬ USD. In the next quarter, revenue is expected to reach ‪379.21 K‬ USD.
ACIU net income for the last quarter is ‪−18.00 M‬ USD, while the quarter before that showed ‪6.35 M‬ USD of net income which accounts for −383.48% change. Track more AC Immune SA financial stats to get the full picture.
No, ACIU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 30, 2025, the company has 172 employees. See our rating of the largest employees — is AC Immune SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AC Immune SA EBITDA is ‪−56.66 M‬ USD, and current EBITDA margin is −184.40%. See more stats in AC Immune SA financial statements.
Like other stocks, ACIU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AC Immune SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AC Immune SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AC Immune SA stock shows the sell signal. See more of AC Immune SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.